



INDEX

SR. NO.	TOPIC	PAGE NO.
	Title Page	I
	Certificate	II
	Declaration	III
	Acknowledgements	IV
CHAPTER 1		
INTRODUCTION		
1	Introduction	1
1.1	Importance of Analytical Methods	1
1.2	Introduction to Analytical Methods	1
1.2.1	Chromatography Techniques	1
	A. High Performance Liquid Chromatography (HPLC)	2
	a. Normal phase HPLC	3
	b. Reversed phase HPLC	3
	B. High Performance Thin Layer chromatography (HPTLC)	7
	C. Infra red spectroscopy	7
1.3	Validation of analytical methods	8
1.3.1	Validation Parameters	10
	Accuracy	10
	Precision	11
	Specificity	11
	Detection limit	12
	Quantitation limit	12
	Linearity	12
	Range	13
	Robustness	13
1.3.2	System suitability tests (sst)	14
	Plate number or number of theoretical plates	14
	Capacity factor (capacity ratio)	15
	Separation factor (relative retention)	15
	Peak resolution r	15
	Peak asymmetry factor (tf)	16
1.3.3	Stability indicating assay method	17
1.4	References	19
CHAPTER 2		
OBJECTIVES		21
CHAPTER 3		
DRUG PROFILE		
3	Drug Profile	24
3.1	Butenafine Hydrochloride	24
3.2	Betamethasone dipropionate	25
3.3	Albendazole	26

3.4	Etizolam	27
3.5	Escitalopram Oxalate	28
3.6	Fluocinolone acetonide	29
3.7	Miconazole nitrate	30
3.8	Hydrocortisone acetate	31
3.9	Racecadotril	32
3.10	Ivermectin	33
3.11	References	34

CHAPTER 4

LITERATURE SURVEY

4	Literature Survey	37
4.1	Butenafine hydrochloride	37
4.1.1.	Simultaneous HPLC Determination of Butenafine Hydrochloride and Betamethasone in a Cream Formulation	37
4.1.2	Stability-Indicating LC Assay for Butenafine Hydrochloride in Creams Using an Experimental Design for Robustness Evaluation and Photodegradation Kinetics Study	37
4.2	Betamethasone Dipropionate	38
4.2.1	Densitometric determination of betamethasone dipropionate and salicylic acid in lotions, and validation of the method	38
4.2.2	Development and validation of a stability-indicating HPLC method for simultaneous determination of salicylic acid, betamethasone dipropionate and their related compounds in Diprosalic Lotion.	38
4.2.3	Development and validation of a stability-indicating RP-HPLC method for simultaneous assay of betamethasone dipropionate, chlorocresol, and for the estimation of betamethasone dipropionate related compounds in a pharmaceutical cream and ointment.	39
4.3	Escitalopram oxalate	39
4.3.1	Spectrophotometric and reversed-phase high-performance liquid chromatographic methods for simultaneous determination of escitalopram oxalate and clonazepam in combined tablet dosage form	39
4.3.2	Simultaneous HPTLC Determination of Escitalopram Oxalate and Clonazepam in Combined Tablets .	40
4.3.3	Development and validation of liquid chromatographic method For estimation of escitalopram oxalate in tablet dosage forms.	40
4.3.4	Colorimetric method for the estimation of escitalopram oxalate in tablet dosage form	41
4.3.5	Zero order spectrophotometric method for estimation of escitalopram oxalate in tablet formulations	41
4.3.6	Spectrophotometric Method for Simultaneous Estimation of Escitalopram Oxalate and Clonazepam in Tablet Dosage Form	41

4.3.7	Study on Pharmacokinetics of Escitalopram Oxalate Tablets in Human Body	41
4.3.8	Pharmacokinetics of escitalopram in healthy volunteers	42
4.3.9	Method for the estimation of escitalopram in bulk and in dosage Forms	42
4.4	Etizolam	43
4.4.1	Simple method for the determination of benzodiazepines in human body fluids by high-performance liquid chromatography–mass spectrometry	43
4.4.2	Rapid and sensitive detection of benzodiazepines and zopiclone in serum using high-performance thin-layer chromatography	43
4.4.3	Effects of different cyclodextrins on the morphology, loading and release properties of poly (DL-lactide-co-glycolide)-microparticles containing the hypnotic agent etizolam	43
4.4.4	Simultaneous determination of etizolam, triazolam and their metabolites by gas chromatography tandem mass spectrometry.	43
4.5	Albendazole	43
4.5.1	Developing a Spectrophotometric method for the estimation of Albendazole in solid and suspension forms	43
4.5.2	RP-HPLC Method for Simultaneous Estimation of Levamisole, Mebendazole and Albendazole in Pharmaceutical Products	43
4.5.3	Quantification of Albendazole in Dewormer Formulations in the Kenyan market	44
4.5.4	Validated UV Spectrophotometric Method for estimation of Albendazole in Tablet	44
4.5.5	A Bioequivalence Study of an Albendazole Oral Suspension Produced in Iran and a Reference Product in Sheep	45
4.6	Ivermectin	45
4.6.1	Liquid chromatographic assay of ivermectin in human plasma for application to clinical pharmacokinetic studies	45
4.6.2	Simultaneous Analysis of Ivermectin and Clorsulon in Injection Solutions by High Performance Liquid Chromatography with Confirmation by Liquid Chromatography Mass Spectrometry	46
4.6.3	Determination of ivermectin stability by high-performance thin-layer	46
4.7	Racecadotril	47
4.7.1	New spectrophotometric methods for the determination of racecadotril in bulk drug and capsules	47
4.7.2	Development and validation of a rapid RP-HPLC method for the determination of Racecadotril in formulation	49
4.7.3	Spectrophotometric and spectrofluorimetric methods for determination of racecadotril	49
4.7.4	Determination of racecadotril and its impurities by HPLC	49
4.8	Fluocinolone acetonide	50

4.8.1	Development of a reversed-phase HPLC method for analysis of fluocinolone acetonide in gel and ointment	50
4.8.2	Determination of fluocinolone acetonide in pharmaceutical preparations by differential-pulse polarography	50
4.8.3	Analysis of creams (objective reference) Quantitative determination of drugs in creams by UV spectrophotometry	50
4.9	Hydrocortisone acetate	51
4.9.1	Optimization and validation of an RP-HPLC method for analysis of hydrocortisone acetate and lidocaine in suppositories.	51
4.9.2	Analysis of hydrocortisone acetate ointments and creams by high-performance liquid chromatography.	51
4.9.3	Optimisation of a Selective Liquid Chromatography Procedure for Hydrocortisone Acetate, Hydrocortisone Alcohol and Preservatives in a Pharmaceutical Emulsion	52
4.9.4	Simultaneous determination of methylparaben, propylparaben, hydrocortisone acetate and its degradation products in a topical	52
4.9.5	Comparison of HPLC and multivariate regression methods for hydrocortisone and lidocaine analysis of pharmaceutical preparation.	53
4.10	REFERENCES	54

CHAPTER 5

EXPERIMENTAL, RESULT & DISCUSSION

5	Experimental, Result & Discussion	58
5.1	HPLC Methods	58
5.1.a	Apparatus and software for HPLC measurement	58
5.1.b	Apparatus and software for HPTLC measurement	59
5.1.1	RP-HPLC Method for Simultaneous Determination of Butenafine Hydrochloride and Betamethasone Dipropionate in a Cream Formulation	60
5.1.1.1	Experimental	60
	Reagents	60
	Chromatographic condition	60
	Method Validation	62
5.1.1.2	Results and Discussion	63
5.1.2	RP-HPLC Method for Simultaneous Determination of Escitalopram oxalate and Etizolamin tablet formulation.	70
5.1.2.1	Experimental	70
	Reagents	70
	Chromatographic conditions	70
	Method Validation	71
5.1.2.2	Results and Discussion	73
5.1.3	Stability indicating RP-HPLC method for simultaneous estimation of Escitalopram Oxalate and Etizolam in a Tablet	80
5.1.3.1	Experimental	80

	Reagents	80
	Chromatographic condition	80
	Method Validation	82
5.1.3.2	Results and Discussion	83
5.1.4	Application of developed RP HPLC method for the dissolution studies of etizolam and escitalopram oxalate	93
5.1.4.1	Experimental	94
5.1.4.2	Results and Discussion	95
5.1.5	RP-HPLC Method for Simultaneous Determination Fluocinolone acetonide and Miconazole Nitrate in an Ointment Formulation	95
5.1.5.1	Experimental	95
	Reagents	95
	Chromatographic conditions	95
	Method Validation	96
5.1.5.2	Results and Discussion	98
5.1.6	RP-HPLC method for simultaneous estimation of Hydrocortisone acetate and Miconazole nitrate in a Cream Formulation	106
5.1.6.1	Experimental	106
	Reagents	106
	Chromatographic conditions	106
	Method Validation	107
5.1.6.2	Results and Discussion	109
5.1.7	A stability indicating validated RP-HPLC Assay Method for Racecadotril in bulk and in formulation (Oral Powder)	115
5.1.7.1	Experimental	115
	Reagents	115
	Chromatographic conditions	115
	Method Validation	116
5.1.7.2	Results and Discussion	118
5.2	HPTLC METHOD	124
5.2.1	Simultaneous HPTLC Determination of Albendazole and Ivermectin From Their Combined Dosage Form	124
5.2.1.1	Experimental	124
	Reagents	124
	Chromatographic conditions	124
	Method Validation	125
5.2.1.2	Results and Discussion	126
5.2.2	Simultaneous Reverse Phase HPTLC Determination of Betamethasone dipropionate and Butenafine hydrochloride in a cream formulation	130
5.2.2.1	Experimental	130
	Reagents	131
	Chromatographic conditions	131
	Method Validation	131
5.2.2.2	Results and Discussion	132

5.3	IR METHOD	137
5.3.1	Development of IR spectroscopic method for the estimation of Albendazole and Ivermectin in combined tablet dosage form	137
5.3.2	Results and discussion	

CHAPTER 6		139
SUMMARY AND CONCLUSION		

6.1	HPLC methods	140
6.1.1	RP-HPLC Method for Simultaneous Determination of Butenafine Hydrochloride and Betamethasone Dipropionate in bulk and in a Cream Formulation	140
6.1.2	RP-HPLC method for simultaneous determination of Escitalopram Oxalate and Etizolam in bulk and in a Tablet Formulation.	140
6.1.3	Stability indicating RP-HPLC method for simultaneous estimation of Escitalopram Oxalate and Etizolam in a Tablet Formulation	141
6.1.4	Application of developed RP HPLC method for the dissolution studies of etizolam and escitalopram oxalate in a tablet dosage form.	141
6.1.5	RP-HPLC Method for Simultaneous Determination Fluocinolone acetonide and Miconazole Nitrate in bulk and in an Ointment Formulation.	142
6.1.6	RP-HPLC method for simultaneous estimation of Hydrocortisone acetate and Miconazole nitrate in bulk and in a Cream Formulation	142
6.1.7	A stability indicating validated RP-HPLC Assay Method for Racecadotril in bulk and in formulation (Oral Powder)	143
6.2	HPTLC METHODS	143
6.2.1	Simultaneous HPTLC Determination of Albendazole and Ivermectin in bulk and in tablet dosage form	143
6.2.2	Simultaneous Reverse Phase HPTLC Determination of Betamethasone dipropionate and Butenafine hydrochloride in a cream formulation	143
6.3	IR Method	144
6.4	Conclusion	144

PUBLICATIONS		145
---------------------	--	-----
